Since Mark’s diagnosis in 2000, he has been committed to the fight against ALS on many levels. Over the past 21 years, he has advocated locally at the state level and nationally on Capitol Hill. He’s volunteered at innumerous events with The ALS Association Mid-America Chapter and served on the Chapter’s board and Services Committee. All who know him say his ALS diagnosis does not define him, instead it motivates him to do more and to give hope to others.
Shares of Amylyx Pharmaceuticals are falling again, despite the company announcing positive long-term survival analysis data for AMX0035, its experimental amyotrophic lateral sclerosis (ALS) therapy that is up for potential approval from the U.S. Food and Drug Administration next month.
The San Francisco Women Artists Gallery is collaborating with the ALS Association Golden West Chapter to raise awareness about the disease throughout May.
May is celebrated as ALS awareness month. Amyotrophic lateral sclerosis, known as ALS or Lou Gehrig’s Disease, is a fatal condition that affects parts of the nervous system. Most patients with the disease are expected to live two to five years after their diagnosis.
FDA has approved Radicava ORS (edaravone) oral suspension for the treatment of adults with amyotrophic lateral sclerosis (ALS). Radicava ORS is an orally administered version of Radicava, which was originally approved in 2017 as an intravenous (IV) infusion to treat ALS, commonly referred to as Lou Gehrig’s disease.